Eli Lilly posts long-term data for eczema therapy Ebglyss
Eli Lilly (NYSE:LLY) on Friday said that its recently approved eczema therapy Ebglyss led to complete skin clearance in 50% ...
Fierce Pharma2d
Texas court decision prevents compounders from producing knockoffs of Eli Lilly's tirzepatide
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh® (mirikizumab-mrkz) for the treatment of moderately to severely active ...
Court denying compounders’ motion positive for Eli Lilly, says Morgan Stanley
Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a ...
Eli Lilly to build 4 more manufacturing sites in US
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the ...
Modern Healthcare3d
Teladoc, LifeMD partner with Eli Lilly on GLP-1s
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
Fierce Pharma9d
Lilly promotes 'healthy skepticism' toward compounded drugs in new Oscars ad campaign
Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
PharmiWeb42m
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily, oral ...